Author Archives: admin

Vor Biopharma Appoints Matthew R. Patterson to its Board of Directors – BioSpace

Oct. 20, 2020 12:00 UTC

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced the appointment of Matthew R. Patterson, a biotechnology executive with nearly 30 years of experience in research, development, and commercialization of innovative treatments, to its Board of Directors.

Matt is a highly respected leader in biotech, and for good reason, said Robert Ang, MBBS, MBA, Vors President and Chief Executive Officer. His expertise, guidance, and insights will be critical as we continue to advance our science towards the goal of developing potentially transformative therapies for patients with blood cancers.

Mr. Patterson has held senior leadership positions in both private and publicly-traded biotechnology companies. He is the co-founder of Audentes Therapeutics and was its Chief Executive Officer for eight years until its acquisition by Astellas Pharma in 2020; he also chaired the companys Board of Directors and continues to serve as a strategic advisor to the company. Additionally, he is a member of the Board of Directors of Homology Medicines, Inc., and the Board of Directors of 5:01 Acquisition Corp. Mr. Patterson also currently serves as the Chairman of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector.

Prior to Audentes, Mr. Patterson was an entrepreneur-in-residence with OrbiMed. Earlier in his career, he worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Mr. Patterson received his bachelors degree in biochemistry from Bowdoin College.

Vors innovative approach to cell therapy and passionate team have the potential to transform the lives of cancer patients, Mr. Patterson said. I am excited to provide guidance and mentorship to Robert and the team as they continue to build a world class cell therapy company.

About Vor Biopharma

Vor Biopharma aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies. By removing biologically redundant proteins from eHSCs, these cells become inherently invulnerable to complementary targeted therapies while tumor cells are left susceptible, thereby unleashing the potential of targeted therapies to benefit cancer patients in need.

Vors platform could be used to potentially change the treatment paradigm of both hematopoietic stem cell transplants and targeted therapies, such as antibody drug conjugates, bispecific antibodies, and CAR-T cell treatments.

Vor is based in Cambridge, Mass. and has a broad intellectual property base, including in-licenses from Columbia University, where foundational work was conducted by inventor and Vor Scientific Board Chair Siddhartha Mukherjee, MD, DPhil.

About VOR33

Vors lead product candidate, VOR33, consists of engineered hematopoietic stem cells (eHSCs) that lack the protein CD33. Once these cells are transplanted into a cancer patient, we believe that CD33 will become a far more cancer-specific target, potentially avoiding toxicity to the normal blood and bone marrow associated with CD33-targeted therapies. Vor aims to improve the therapeutic window and effectiveness of CD33-targeted therapies, thereby potentially broadening the clinical benefit to patients suffering from acute myeloid leukemia.

View source version on

Read more from the original source:
Vor Biopharma Appoints Matthew R. Patterson to its Board of Directors - BioSpace

Five Penn faculty elected to the National Academy of Medicine – Penn Today

Five faculty members from Penn have been elected to the National Academy of Medicine (NAM), one of the nations highest honors in the fields of health and medicine. William Beltran of the School of Veterinary Medicine, Matthew McHugh of the School of Nursing, and Ronald DeMatteo, Raina Merchant, and Hongjun Song of the Perelman School of Medicine are among the 100 new members, elected by current NAM members.

Election recognizes individuals who have made major contributions to the advancement of the medical sciences, health care, and public health.

William Beltran is professor of ophthalmology in the Department of Clinical Sciences and Advanced Medicine and director of the Division of Experimental Retinal Therapies at Penn Vet. His research focuses on inherited retinal degeneration, a major cause of blindness in dogs and humans worldwide. Specifically, he has investigated the signaling pathways affected by X-linked retinitis pigmentosa and autosomal dominant retinitis pigmentosa, two of the most common forms of inherited retinal degeneration in humans. Working in canines, who suffer from forms of retinal degeneration that closely mimic the human diseases, he has helped develop effective gene therapies with promising results for treating both early- and late-stage disease.

Ronald Paul DeMatteo is the John Rhea Barton Professor and chair in the Perelman School of Medicines Department of Surgery. DeMatteo served as principal investigator on three national trials for the adjuvant drug imatinib for gastrointestinal stromal tumor, the most common human sarcoma. His work led to imatinibs approval for adjuvant use by the FDA and established the standard-of-care for GIST, combining surgery and imatinib. DeMatteo is also being recognized for his work to define the immune response to GIST and its modulation by targeted therapy.

Matthew McHugh is the Independence Chair for Nursing Education and professor of nursing at Penn Nursing, associate director of the Center for Health Outcomes and Policy Research (CHOPR), and senior fellow of the Leonard Davis Institute of Health Economics. As principal investigator on multiple large-scale studies funded by the National Institutes of Health, Agency for Healthcare Research and Quality, and Robert Wood Johnson Foundation, McHughs work has advanced the field of nursing outcomes and policy research by showing the value of investing in nursing to achieve a higher functioning health care system. In addition to findings from direct evaluations of nurse staffing ratio laws, research from McHugh and colleagues from the CHOPR at Penn Nursing has informed legislation proposed in multiple states and countries on safe nurse-staffing levels.

Raina Merchant is associate vice president and director of the Center for Digital Health in Penn Medicine and associate professor of emergency medicine in the Perelman School of Medicine.Merchants work has sought to gain insights through digital media about important health trends, and she is recognized for developing, deploying, evaluating, and refining novel tools and techniques to promote individual and population health. Some of her projects in this arena include tracking both physical and mental health symptoms via Twitter during the COVID-19 pandemic, determining keywords and phrases that could be used to flag depression via Facebook posts, and a crowdsourcing initiative called the MyHeartMap Challenge to construct an online map of automated external defibrillators across Philadelphia. In 2019, Merchant was named to NAMs class of Emerging Leaders of Health and Medicine Scholars.

Hongjun Song is the Perelman Professor of Neuroscience in the Perelman School of Medicines Department of Neuroscience and co-director of the Institute for Regenerative Medicine Neurodevelopment and Regeneration Program. His work focuses on neural stem cell regulation and neurogenesis and their effects on neural function as well as epigenetic and epitranscriptomic mechanisms and their role in the mammalian nervous system. He is being recognized for revealing unexpected dynamics and plasticity of the neuronal epigenome, as well as its functions under physiological and pathological conditions. In response to urgent global health concerns, his team made a series of timely discoveries on the pathogenesis, mechanisms, and treatment of Zika virus infections.

See the original post here:
Five Penn faculty elected to the National Academy of Medicine - Penn Today

Accident & Injury Solutions Is the Place to Throw Light on Regenerative Medicine in Mesa and Phoenix, Arizona – Press Release – Digital Journal

Individuals looking for treatment for injuries or Osteoarthritis can get in touch with Accident & Injury Solutions.

This press release was orginally distributed by ReleaseWire

Scottsdale, AZ -- (ReleaseWire) -- 10/19/2020 -- Not many are aware of the importance of regenerative medicine, which can help treat several physical ailments. Injuries can result out of nowhere, and most of the time, these injuries are from overuse. Individuals can suffer from tennis elbow or rotator cuff repair, and golfer's nee. Those facing these ailments have a hard time healing the damaged tissues that include cartilage tendons and ligament. As time passes, these deteriorate further and are often damaged beyond regeneration on own. Some intervention is required, and the role is usually played by regenerative medicine.

Finding the right place to help with regenerative medicine Mesa and Phoenix, Arizona is essential for the desired results. For that, one can get in touch with Accident & Injury Solutions. They are the ones who have been doing a great job in bringing the best regenerative medicine to their patients with Platelet Rich Plasma (PRP) and Stem Cell Therapy Injections. There are a good number of injuries that can be successfully treated with regenerative medicine. Muscle strains, ligament sprains, injured tendons, inflamed joints, and Osteoarthritis can be treated successfully with regenerative medicine.

Accident & Injury Solutions has had great success with outcomes and helping patients get back their quality of life. Part of this is due to the high quality of materials that are being administered to the patients. They consider the source for stem cells one of the best. They come from amniotic fluid that has proven to be an excellent source for tissue growth and regeneration.

The company also offers physical therapy in Mesa and Phoenix, Arizona. With proper and timely physical therapy, individuals might be able to battle effectively the pain and issues resulting from injuries.

Call 602-466-9664 for more details.

About Accident & Injury Solutions Accident & Injury Solutions is a renowned company that has been serving for the best interest of its clients for long. They can arrange for physical therapy in Mesa and Phoenix, Arizona apart from administering regenerative medicine.

For more information on this press release visit:

View post:
Accident & Injury Solutions Is the Place to Throw Light on Regenerative Medicine in Mesa and Phoenix, Arizona - Press Release - Digital Journal

Kim Kardashians changing face as she hits 40 and why shes probably about to reach for the Botox – The Sun

KIM Kardashian is celebrating her 40th birthday today - and if you ask us, she looks as good now as she did when Keeping Up with the Kardashians debuted in 2007.

Over the past 13 years, Kim has established herself as a savvy businesswoman (estimated to be worth 670m) and is now a proud mum-of-four.

But while there's no denying the Kardashians have influenced our fashion choices over the years , we also have Kim to thank for our full-blown obsession with contouring.

Here Fabulous Digital takes a look back at Kim's changing face as the social media icon turns 40.

If old episodes of Keeping Up with the Kardashians are anything to go by, Kim might just feel brave enough to give Botox another go now she's 40 years old.


In season five of the hit series, Kim - who was 30 at the time - took sister Khlo along for moral support as she tried Botox for the first time.

Ahead of the appointment, Kim said: "I'm going to try Botox to get rid of my wrinkles and once and for all I'm going to see what it's all about."

The star visited Lift MD Aesthetics in Beverly Hills where she had Botox injected near her temples.

In the days that followed, Kim says the area where she'd been injected was swollen, sore and itchy - which prompted her to swear off Botox for another ten years.

While out for lunch with Khlo, Kim asked for a glass of ice and said her eyes felt like they were "on fire".

Although Kim feared she'd had an allergic reaction to the Botox, her family doctor Dr Vaisman confirmed that bruising was a normal yet uncomfortable side effect of the procedure.

After the swelling eventually went down, Kim said: "I'll never do this again... at least, not until I'm 40."

Over the past 13 years, Kim has proved she isn't afraid to experiment with her hair - changing from luscious long locks to cropped blonde bobs in a heartbeat.

But in 2015, the star admitted that she'd had laser hair removal on her forehead to get a more defined hair line.

She told People magazine: "I have the hairiestforehead you could ever imagine, and I would always break out.

"In high school, I would wax it off because there was just so much hair."


A year later, Kim admitted in a blog post on her website that she regretted having the permanent laser treatment.

She wrote: "Every photographer would Photoshop them out anyway, and I thought I looked better without the baby hairs, but now I miss them."

If there's one thing we know about Kim Kardashian - it's that she's doesn't shy away from experimental beauty treatments... no matter how uncomfortable they may be.



In 2013, the star hit headlines when she tried out the experimental "vampire facial" while filming Kourtney & Kim Take Miami.

The actual name for a vampire facial is Platelet Rich Plasma (PRP) Therapy which uses nothing but the patient's own blood to plump the skin.

Platelets are tiny blood cells which play a crucial part in helping the body stop bleeding - as well as repairing damaged blood vessels and cells.

In PRP, a needle is used to draw blood from the client's arm. The blood is then spun in a machine, to remove the platelets.

Although patients are offered local anaesthetic cream before the injections, Kim told W magazine in 2018that she'd refused painkillers because she'd just found out she was pregnant with North.

She said: "Before I got the procedure, I just found out that I was pregnant, so I couldnt use numbing cream or a pain killer and both are suggested.

"It was really rough and painful for me."

Last year, Kim tried out the the Exilis Laser 360 facial which uses radio frequency and an ultrasound technology laser to tighten skin.

The treatment also stimulates collagen production which makes the skin look plumper.

Reality star, social media icon, mum-of-four, multimillionaire - there are a lot of things you can call Kim Kardashian... but "Queen of Contour" is our personal favourite.

Although Hollywood starlets had used contouring to highlight their cheekbones, Kim brought it to the mainstream in 2012 when she shared a photo of her lengthy make-up routine.

Makeup artist Scott Barnes started by using a generous amount of light concealer under Kim's eyes along her nose.

He then went in with a cream bronzer underneath Kim's cheekbones to create a natural-looking shadow.



And just like that, Kim kickstarted a beauty craze which meant we could all fake the perfect bone structure.

The star has since gone on to launch her own contouring products as part of her KKW line.

However, in 2016 Kim said she was "over contouring".

Speaking on a panel with Charlotte Tilbury, she said: "I think right now it's more about nontouring, like real skin with less make-up on it.

"I'm trying to wear less... and my husband loves me without make-up."

It's safe to say that beauty trends have come a LONG way since Kim first rose to fame 13 years ago.

In the noughties, brows were thin and defined and it was all about the smokey eye.

She previously told TODAY: "In the 90s, in high school, I would make my brows so thin!"

According to Cult Beauty, the star loves Anastasia Beverly Hills' 15 brow pomade so much that she even used it on her wedding day to Kanye.


Kim reportedly maintains her brows with professional waxing and trimming appointments too.

And just because she has access to the world's top make-up artists, that doesn't stop Kim from using a beauty bargain from time-to-time.

In a YouTube beauty tutorial, Kim's make-up artist Mario Dedivanovic raved about Ardell's 5 false lashes.

Explaining how he combines different lengths to create a fluttery effect on the star, he said: "I like to useArdell DuraLash Naturalsin Medium and Long." *Adds to basket*

For more celebrity stories, these reality stars are morphing into each other as Kady McDermott goes full Maura & Vicky Pattison gets a Towie clone.

And Gemma Atkinson opened up to Fabulous magazine about mum life, taking on haters & keeping things hot with Gorka.

Plus Meghan wore 300k worth of jewellery and clothes in new pic to promote show on building a better digital world.

Kim Kardashians changing face as she hits 40 and why shes probably about to reach for the Botox - The Sun

Turning Point Therapeutics Announces Abstract For TRIDENT-1 Clinical Study of Repotrectinib Accepted For Presentation at World Conference on Lung…

SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that an abstract for the TRIDENT-1 clinical study of its lead drug candidate repotrectinib has been selected for a mini-oral presentation on Jan. 31, 2021 at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer.

See more here:
Turning Point Therapeutics Announces Abstract For TRIDENT-1 Clinical Study of Repotrectinib Accepted For Presentation at World Conference on Lung...

AzurRx BioPharma Announces Formation of Scientific Advisory Board

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) --  AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced the formation of a Scientific Advisory Board (SAB) including three of the leading global experts in exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.

See the original post here:
AzurRx BioPharma Announces Formation of Scientific Advisory Board

Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio

NEWARK, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies to treat cancer, today announced that it has entered into a research collaboration and commercial license agreement with ArsenalBio for the use of Teneobio’s UniDabs®, single-domain, human heavy chain only antibodies in Chimeric Antigen Receptor (CAR) T-cell therapy.

Read this article:
Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio

Paratek Pharmaceuticals Presenting New Data on NUZYRA® (Omadacycline) at IDWeek 2020

Key Highlights Include Data on NUZYRA as an Alternative to Standard of Care to Reduce Clostridioides Difficile Infections and Real-World Experience with NUZYRA for Nontuberculous Mycobacterial and MDR/XDR Gram Negative Infections Key Highlights Include Data on NUZYRA as an Alternative to Standard of Care to Reduce Clostridioides Difficile Infections and Real-World Experience with NUZYRA for Nontuberculous Mycobacterial and MDR/XDR Gram Negative Infections

Read the original:
Paratek Pharmaceuticals Presenting New Data on NUZYRA® (Omadacycline) at IDWeek 2020